# Corcept Therapeutics clinical trials: 73 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 73 trials with Corcept Therapeutics as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Corcept Therapeutics: 73 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/corcept-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 73
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 73, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 28, 2026 | NCT07553663 | Evaluating the Pharmacokinetics and Safety of Miricorilant | Corcept Therapeutics | Phase 1 | Completed | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic... | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553663) |
| December 11, 2025 | NCT07276373 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | Corcept Therapeutics | Phase 1/2 | Recruiting | Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276373) |
| December 2, 2025 | NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Corcept Therapeutics | Phase 2 | Recruiting | Adenocarcinoma, Carcinoma, Pancreatic Ductal | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07259317) |
| November 20, 2025 | NCT07240116 | Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects | Corcept Therapeutics | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240116) |
| April 27, 2025 | NCT06947304 | Evaluation of Miricorilant on Liver Fat in Patients With MASLD | Corcept Therapeutics | Phase 1 | Completed | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947304) |
| April 15, 2025 | NCT06928779 | Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant | Corcept Therapeutics | Phase 1 | Completed | Hepatic Impairment | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06928779) |
| April 2, 2025 | NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Corcept Therapeutics | Phase 2 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06906341) |
| February 17, 2025 | NCT06829537 | Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) | Corcept Therapeutics | Observational | Completed | Resistant Hypertension, Hypercortisolism | 1,143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06829537) |
| July 11, 2024 | NCT06495944 | Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants | Corcept Therapeutics | Phase 1 | Completed | Healthy Adults | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06495944) |
| October 30, 2023 | NCT06108219 | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated... | Corcept Therapeutics | Phase 2 | Completed | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06108219) |
| October 23, 2023 | NCT06094790 | A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects | Corcept Therapeutics | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094790) |
| October 23, 2023 | NCT06094738 | A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects | Corcept Therapeutics | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094738) |
| October 23, 2023 | NCT06094725 | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant | Corcept Therapeutics | Phase 1 | Completed | Hepatic Impairment | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094725) |
| October 23, 2023 | NCT06094712 | A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects | Corcept Therapeutics | Phase 1 | Completed | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094712) |
| March 16, 2023 | NCT05772169 | Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) | Corcept Therapeutics | Phase 4 | Completed | Hypercortisolism, Diabetes Mellitus, Type 2 | 1,113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05772169) |
| February 3, 2023 | NCT05712265 | Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | Corcept Therapeutics | Phase 1 | Completed | Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05712265) |
| September 23, 2022 | NCT05553470 | Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | Corcept Therapeutics | Phase 1 | Completed | Non-alcoholic Steatohepatitis (NASH) | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05553470) |
| June 7, 2022 | NCT05407324 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Corcept Therapeutics | Phase 2 | Active not recruiting | Amyotrophic Lateral Sclerosis | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05407324) |
| April 27, 2022 | NCT05347979 | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants | Corcept Therapeutics | Phase 1 | Completed | Cushing Syndrome, Neoplasms | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05347979) |
| April 11, 2022 | NCT05320146 | A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic... | Corcept Therapeutics | Observational | Completed | Nonalcoholic Steatohepatitis (NASH) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05320146) |
| February 25, 2022 | NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or... | Corcept Therapeutics | Phase 3 | Active not recruiting | Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05257408) |
| November 11, 2021 | NCT05117489 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | Corcept Therapeutics | Phase 1 | Completed | Nonalcoholic Steatohepatitis (NASH) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05117489) |
| August 12, 2021 | NCT05003713 | Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants | Corcept Therapeutics | Phase 1 | Completed | Healthy | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05003713) |
| August 6, 2021 | NCT04994743 | Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants | Corcept Therapeutics | Phase 1 | Completed | Healthy Adults | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04994743) |
| August 4, 2021 | NCT04990310 | Single Dose Absorption, Distribution, Metabolism, and Excretion Study of \[14C\]-CORT113176 in Healthy Male Participants | Corcept Therapeutics | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04990310) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 37 |
| Phase 1/2 | 3 |
| Phase 2 | 12 |
| Phase 3 | 14 |
| Phase 4 | 1 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 59 |
| Terminated | 7 |
| Recruiting | 3 |
| Active not recruiting | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Cushing Syndrome | 16 |
| ACTH Syndrome, Ectopic | 9 |
| Pituitary ACTH Hypersecretion | 8 |
| Non-alcoholic Fatty Liver Disease | 8 |
| Diabetes Mellitus, Type 2 | 6 |
| Adrenal Cortex Neoplasms | 6 |
| Psychotic Disorders | 6 |
| Hypertension | 5 |
| Depressive Disorder, Major | 5 |
| Depression | 5 |
| Pituitary Diseases | 4 |
| Ovarian Neoplasms | 4 |
| Choristoma | 3 |
| Hirsutism | 3 |
| Fallopian Tube Neoplasms | 3 |
| Weight Gain | 3 |
| Adrenocortical Carcinoma | 3 |
| Neoplasms | 3 |
| Prostatic Neoplasms | 2 |
| Obesity | 2 |
| Mental Disorders | 2 |
| Schizophrenia | 2 |
| Peritoneal Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Adenocarcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Vehicle shipping companies in the United States](https://specstream.ai/data/businesses/vehicle-shipping-companies/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Emergency and urgent care facilities in the United States](https://specstream.ai/data/businesses/emergency-and-urgent-care-facilities/united-states)
- [Refinishing companies in the United States](https://specstream.ai/data/businesses/refinishing-companies/united-states)
- [Contractors in the United States](https://specstream.ai/data/businesses/contractors/united-states)
